In today’s recent session, 1.37 million shares of the Aldeyra Therapeutics Inc (NASDAQ:ALDX) have been traded, and its beta is 1.35. Most recently the company’s share price was $4.96, and it changed around $0.75 or 17.81% from the last close, which brings the market valuation of the company to $291.21M. ALDX at last check was trading at a discount to its 52-week high of $6.55, offering almost -32.06% off that amount. The share price’s 52-week low was $2.43, which indicates that the recent value has risen by an impressive 51.01% since then. We note from Aldeyra Therapeutics Inc’s average daily trading volume that its 10-day average is 0.52 million shares, with the 3-month average coming to 446.51K.
Aldeyra Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ALDX as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Aldeyra Therapeutics Inc is expected to report earnings per share of -0.23 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Instantly ALDX has been showing a green trend so far today with a performance of 17.81% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 5.42 on recent trading dayincreased the stock’s daily price by 8.49%. The company’s shares are currently up 41.31% year-to-date, but still down -9.66% over the last five days. On the other hand, Aldeyra Therapeutics Inc (NASDAQ:ALDX) is -12.98% down in the 30-day period. We can see from the shorts that 3.67 million shares have been sold at a short interest cover period of 8.67 day(s).
The consensus price target as assigned by Wall Street analysts is $11, which translates to bulls needing to increase their stock price by 54.91% from its current value. Analyst projections state that ALDX is forecast to be at a low of $10 and a high of $12.
Aldeyra Therapeutics Inc (ALDX) estimates and forecasts
Aldeyra Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 23.07 percent over the past six months and at a -39.06% annual growth rate that is well below the industry average of 15.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -187.50% in revenue this quarter, and will report a decrease of -57.14% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.70%.
ALDX Dividends
Aldeyra Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-05.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.44% of Aldeyra Therapeutics Inc shares, and 62.22% of them are in the hands of institutional investors. The stock currently has a share float of 63.77%. Aldeyra Therapeutics Inc stock is held by 152.0 institutions, with PERCEPTIVE ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 15.6121% of the shares, which is about 9.28 million shares worth $30.7 million.
KNOLL CAPITAL MANAGEMENT, LLC, with 9.2158% or 5.48 million shares worth $18.12 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
